



An Affymetrix Company

# **Anti-Human HLA-DR FITC**

Catalog Number: 11-9956

RUO: For Research Use Only. Not for use in diagnostic procedures.





Staining of normal human peripheral blood cells with Mouse IgG2b K Isotype Control FITC (cat. 11-4732) (blue histogram) or Anti-Human HLA-DR FITC (purple histogram). Cells in the lymphocyte (left) or monocyte (right) gate were used for analysis.

#### **Product Information**

Contents: Anti-Human HLA-DR FITC


REF Catalog Number: 11-9956

Clone: LN3

Concentration: Suffix -73, 20 uL (0.125 ug)/test; Suffix -42, 5 uL (0.125 ug)/test Host/Isotype: Mouse IgG2b, kappa



**Formulation:** aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer **Temperature Limitation:** Store at 2-8°C. Do not





Use By: Refer to vial

## Description

The LN3 mAb reacts with the human major histocompatibility complex (MHC) class II, HLA-DR. HLA-DR is expressed on the surface of human antigen presenting cells (APC) including B cells, monocytes, macrophages, DCs, and activated T cells. HLA-DR is a heterodimeric transmembrane protein composed of  $\alpha$  and  $\beta$  subunits and plays an important role in the presentation of peptides to CD4<sup>+</sup> T lymphocytes.

### **Applications Reported**

This LN3 antibody has been reported for use in flow cytometric analysis.

#### **Applications Tested**

This LN3 antibody has been pre-titrated and tested by flow cytometric analysis of human peripheral blood leukocytes. Refer to catalog number suffix on the vial for amount to use per test: 73 is 20  $\mu$ L (0.125  $\mu$ g) per test; whereas 42 is 5  $\mu$ L (0.125  $\mu$ g) per test. A test is defined as the amount ( $\mu$ g) of antibody that will stain a cell sample in a final volume of 100  $\mu$ L. Cell number should be determined empirically but can range from 10<sup>5</sup> to 10<sup>8</sup> cells/test.

#### References

Fullen, D. R. and J. T. Headington. 1998. Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas. J Cutan Pathol. 25(10): 553-8.

Hua, Z. X., K. E. Tanaka, et al. 1998. Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. Hum Pathol. 29(12): 1441-6.

loachim, H. L., S. E. Pambuccian, et al. 1996. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol. 20(1): 64-71.

Davey, F. R., S. Olson, et al. 1988. The immunophenotyping of extramedullary myeloid cell tumors in paraffinembedded tissue sections. Am J Surg Pathol. 12(9): 699-707.

Norton, A. J. and P. G. Isaacson. 1987. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies



# **Anti-Human HLA-DR FITC**

Catalog Number: 11-9956

RUO: For Research Use Only. Not for use in diagnostic procedures.

reactive in routinely fixed wax-embedded tissue. Am J Pathol. 128(2): 225-40.

#### **Related Products**

11-4732 Mouse IgG2b K Isotype Control FITC